Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 3 | 3 | 6 |
| 2006 | 8 | 0 | 8 |
| 2007 | 4 | 0 | 4 |
| 2008 | 4 | 0 | 4 |
| 2009 | 1 | 4 | 5 |
| 2010 | 3 | 4 | 7 |
| 2011 | 5 | 1 | 6 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 5 | 8 |
| 2014 | 5 | 3 | 8 |
| 2015 | 8 | 2 | 10 |
| 2016 | 9 | 6 | 15 |
| 2017 | 5 | 1 | 6 |
| 2018 | 4 | 4 | 8 |
| 2019 | 3 | 4 | 7 |
| 2020 | 6 | 4 | 10 |
| 2021 | 4 | 1 | 5 |
| 2022 | 5 | 0 | 5 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer. 2023 01; 11(1).
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
-
Applying mixture cure survival modeling to medication persistence analysis. Pharmacoepidemiol Drug Saf. 2022 07; 31(7):788-795.
-
Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care. Pharmacotherapy. 2022 05; 42(5):428-438.
-
Staging Endovascular Thoracic and Thoracoabdominal Aortic Aneurysm Repairs and the Risk of Post-operative Spinal Cord Ischemia. Ann Vasc Surg. 2022 Sep; 85:299-304.
-
The Magnitude and Potential Causes of Sex Disparities in Statin Therapy in Veterans with Type 2 Diabetes: A 10-year Nationwide Longitudinal Cohort Study. Womens Health Issues. 2022 May-Jun; 32(3):274-283.
-
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2022 Apr; 25(4):707-712.
-
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
-
Statins for treatment of chronic liver disease. Curr Opin Gastroenterol. 2021 05 01; 37(3):200-207.